The presence of discordantly abnormal CSF AD biomarkers could be suggestive of this condition, warranting further evaluation with PET using AD‐tau specific tracers, such as (18F)‐MK6240, to confirm its diagnosis in complex cases. The gene discussed is MAPT; the disease is Alzheimer disease.